Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Said Higher Revenue, Miniscule R&D Tab Helped Trim Losses in Q1

NEW YORK, May 8 - Orchid Bioscience today said that a jump in first-quarter revenue and shrunken R&D spending helped trim net losses.


Total revenue for the period ended March 31 increased to $12.7 million from $11.7 million year over year, Orchid said.


First-quarter R&D spending fell to $1.1 million from $5.4 million in the year-ago period. As a result, net loss narrowed by more than half to $5.2 million, or $.09 per share, from $10.5 million, or $.21 per share, in the first quarter last year.


Orchid said it had approximately $12.4 million in cash and cash equivalents as of March 31.


George Poste, Orchid's chairman, said he "look[s] forward to reporting our progress on recruiting a chief executive officer as well as the divestiture of our Diagnostics business in the near future." Orchid's former CEO, Dale Pfost, resigned in December 2002.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.